After the FDA crackdown: the state of US compounded GLP-1 in May 2026
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.
The April 30 US peptide vendor scorecard recap captured the snapshot at the end of the FDA's enforcement-discretion wind-down. Strive Pharmacy was on conditional verdict with a fresh September 2025 Arizona Board of Pharmacy inspection finding. Empower Pharmacy was on conditional with the April 2025 FDA warning letter and the Eli Lilly federal action still active. Amino Asylum was on hold, offline since the June 2025 raid.
Four weeks later the picture is meaningfully different. This is the May 2026 follow-on read.
What the FDA actually closed
For clarity on what the "crackdown" framing means: the FDA ended enforcement discretion for 503A state-licensed pharmacies on February 18, 2025 (tirzepatide) and April 22, 2025 (semaglutide). For 503B outsourcing facilities the dates were March 19, 2025 and May 22, 2025. After those dates, compounding semaglutide and tirzepatide as essentially-copies of the commercially-available branded products fell outside the FDA's safe-harbor.
The narrow exception the FDA left open is the 503A "four or fewer prescriptions per drug per month per compounder" carve-out for compounders not regularly producing essentially-copies. This was not the volume play the larger 503A operations were running; it is a clinical-edge-case carve-out.
So the crackdown did not ban compounded GLP-1. It tightened the channel to (a) clinically-individualized compounded formulations and (b) the four-or-fewer-per-month threshold for any single 503A. Mass-production-as-essentially-a-copy is what got walled off.
What changed in the May 2026 four-week window
Strive Pharmacy continued to push the boundary of the carve-out. Patient-specific compounded semaglutide and tirzepatide remained on their order pages through April 2026 with personalized-dosing language attached to each prescription. The Eli Lilly Delaware and New Jersey suits remained active. Multiple state board inquiries reportedly in progress (per industry coverage; not yet public). No new FDA warning letter as of this writing.
Empower Pharmacy narrowed compounded GLP-1 production. The April 2025 warning letter remediation work appears to be ongoing per Empower's public statements; the Eli Lilly federal action refiled in Texas in July 2025 remains active. Empower's other 503A and 503B production lines (testosterone, peptides outside GLP-1, sterile compounded medications) appear unaffected.
Pure Rawz, Limitless Life Nootropics as research-chem channels were not directly affected by the FDA compounded-pharmacy enforcement. Their structural ceiling on rx-legality (research-only, no prescription layer) is the same shape it was a month ago. Both continue operating; both maintain the same conditional verdict on our scorecards.
Amino Asylum remains offline. No public movement since the June 2025 enforcement action. The hold-verdict scorecard is the answer to the search query for anyone looking for them now.
What changed for users
For US patients who were on compounded semaglutide or tirzepatide pre-crackdown, three patterns have emerged:
1. Migration to branded. Patients with insurance coverage or with the cash for Wegovy / Mounjaro / Zepbound have moved to the branded products. The commercial supply is stable post-shortage; the price differential remains 4-8x compounded but is real. 2. Migration to telehealth-mediated 503A patient-specific compounding. A subset of telehealth platforms (Hims, Henry Meds, Ro, Mochi) continue to source from 503A compounders within the four-or-fewer-per-month or patient-specific-formulation carve-out. The price stays roughly where it was; the prescription documentation gets more rigorous. 3. Migration to grey-channel research-chem. A subset of patients moved to research-chemical sources (Pure Rawz, Limitless Life, others not in our catalog). Trading up on cost-savings, trading down on the rx-legality structural protection. Our structural-ceiling explainer covers what that channel can and cannot offer.
The matchmaker at /quiz routes US users by region + budget + urgency. The post-crackdown routing currently leans toward telehealth-mediated 503A for users who want continuity at the compounded price band, and toward branded-prescription routes for users who want the cleanest rx-legality posture.
What is still in motion
The FDA's PSE-2026-RFA (proposed rulemaking on bulk-substances exclusion for semaglutide, tirzepatide, and liraglutide) is in comment period through mid-2026. If finalized as proposed, the rule would more permanently close the 503B compounding pathway for these molecules; the 503A patient-specific carve-out would remain.
The Eli Lilly suits against multiple compounded providers (Empower in Texas, Strive in Delaware and New Jersey, additional defendants we are not naming because the suits are unsettled) are at various stages. Settlement or judgment outcomes through 2026 will reset the operational ground for any remaining compounded providers.
The state-board enforcement layer is the next-most-active surface. The Arizona Board's Strive inspection is one example; California, Texas, and Florida boards have all signaled intent to inspect 503A pharmacies producing semaglutide or tirzepatide in volume.
The verdict map, May 2026
| Vendor | April 30 | May 2 | Change |
|---|
Score deltas are within the noise band of the rubric · they do not change the verdict for either Empower or Strive. The picture remains: compounded GLP-1 in the US is operating in a tighter channel than it was 12 months ago, the largest providers are dealing with active legal and regulatory weight, and the structural-ceiling vendors (research-chem) are unaffected by the compounded-pharmacy enforcement specifically.
What we will be watching for the next update
- The Eli Lilly Texas-court trial schedule for the Empower case
- Any FDA warning letter to Strive following the AZ Board inspection findings
- The PSE-2026-RFA comment-period close + finalization timeline
- Whether any new 503A or 503B operator enters the patient-specific-compounded GLP-1 space at meaningful scale
- Any relisting of Amino Asylum or successor entity (we will update the scorecard if so)
The next recap lands when one of these moves materially. In the meantime the individual scorecards carry the per-vendor signal and the 11-signal rubric is the framework we score against.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
Bali GLP-1 supply tactical update May 2026: what's actually in stock at each clinic this month
BPOM intermittency means the existing Bali buyers guide gets stale fast. This is the May 2026 supply-state tactical · per-clinic Mounjaro and Ozempic stocking, the most-current expat-routable picks, and the Bangkok-hop fallback when the nomad-clinic layer has gaps.
The Bangkok GLP-1 hop: a practical playbook for expats in Bali, Singapore, Hanoi, HCMC, KL, Manila
Bangkok is the regional anchor for legitimately-supplied tirzepatide and semaglutide in Southeast Asia. Flight matrices, clinic-relationship cadence, cold-chain transit, customs personal-use rules per origin country, and the four-versus-twelve-week supply math.
Bangkok GLP-1 supply digest · May 2026 · issue 1
Weekly read on what's actually in stock at the Bangkok premium hospitals and mid-tier clinics, with price changes since last digest, regulatory movements that affect supply, and the picking question for this week. New format, weekly cadence, BKK-anchored. Issue 1.